Israel - English - Ministry of Health

dexcel ltd, israel - rivastigmine as hydrogen tartrate - hard capsule - rivastigmine as hydrogen tartrate 1.5 mg - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementiaassociated with parkinson's disease.

Israel - English - Ministry of Health

dexcel ltd, israel - rivastigmine as hydrogen tartrate - hard capsule - rivastigmine as hydrogen tartrate 3 mg - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementiaassociated with parkinson's disease.

Israel - English - Ministry of Health

dexcel ltd, israel - rivastigmine as hydrogen tartrate - hard capsule - rivastigmine as hydrogen tartrate 4.5 mg - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementiaassociated with parkinson's disease.

Israel - English - Ministry of Health

dexcel ltd, israel - rivastigmine as hydrogen tartrate - hard capsule - rivastigmine as hydrogen tartrate 6 mg - rivastigmine - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementiaassociated with parkinson's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rivastigmine hydrogen tartrate, quantity: 9.6 mg (equivalent: rivastigmine, qty 6 mg) - capsule, hard - excipient ingredients: iron oxide red; magnesium stearate; microcrystalline cellulose; titanium dioxide; colloidal anhydrous silica; iron oxide yellow; gelatin; hypromellose; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; allura red ac; povidone; sodium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rivastigmine hydrogen tartrate, quantity: 7.2 mg (equivalent: rivastigmine, qty 4.5 mg) - capsule, hard - excipient ingredients: sodium lauryl sulfate; titanium dioxide; iron oxide red; magnesium stearate; hypromellose; gelatin; colloidal anhydrous silica; iron oxide yellow; microcrystalline cellulose; propylene glycol; ethanol; isopropyl alcohol; shellac; povidone; tert-butyl alcohol; sodium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rivastigmine hydrogen tartrate, quantity: 4.8 mg (equivalent: rivastigmine, qty 3 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; sodium lauryl sulfate; sunset yellow fcf; magnesium stearate; gelatin; brilliant scarlet 4r; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; allura red ac; povidone; sodium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rivastigmine hydrogen tartrate, quantity: 2.4 mg (equivalent: rivastigmine, qty 1.5 mg) - capsule, hard - excipient ingredients: sunset yellow fcf; titanium dioxide; microcrystalline cellulose; iron oxide yellow; sodium lauryl sulfate; gelatin; hypromellose; magnesium stearate; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; allura red ac; povidone; sodium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 2.4 mg - capsule - excipient ingredients: microcrystalline cellulose; stearic acid; gelatin; iron oxide yellow; maize starch; titanium dioxide; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 4.8 mg - capsule - excipient ingredients: titanium dioxide; microcrystalline cellulose; gelatin; maize starch; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type